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Cardiac morbidity
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Patients with PH-HFpEF develop more severe 
symptoms than those with HFpEF and suffer 
significant exercise intolerance, frequent
hospitalizations, RV failure, and reduced survival
Among people >65 years presenting to 
primary care with exertional dyspnoea, 
1 in 6 will have HF (mainly HFpEF)
PV Capillary PA
LA•    Backward pulmonary veins pressure
•    LA pressure
•    LA compliance
LV
• Diastolic 
dysfunction
•    LVEDPRV
• RV remodelling
   and dysfunction
• RV failure
•    RV afterload
•    PVR
•    PA pressure
• Alveolar-capillary stress failure
• Pathological changes in
   pulmonary veins and 
   arteries
Worldwide (2012)
USA (2014)
26 million
patients 
with HF
USA
6.5 million
patients 
with HF
HFpEF:~3.25M
PH-HFpEF:~1.6M
Pulmonary
hypertension 
Abstract Pulmonary hypertension in the setting of heart failure with preserved ejection fraction
(PH-HFpEF) is a growingpublichealthproblemthat is increasing inprevalence.WhilePH-HFpEF
is defined by a high mean pulmonary artery pressure, high left ventricular end-diastolic pressure
and a normal ejection fraction, some HFpEF patients develop PH in the presence of pulmonary
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vascular remodelling with a high transpulmonary pressure gradient or pulmonary vascular
resistance. Ageing, increased left atrial pressure and stiffness, mitral regurgitation, as well as
features ofmetabolic syndrome, which include obesity, diabetes and hypertension, are recognized
as risk factors for PH-HFpEF. Qualitative studies have documented that patients with PH-HFpEF
develop more severe symptoms than those with HFpEF and are associated with more significant
exercise intolerance, frequent hospitalizations, right heart failure and reduced survival. Currently,
there are no effective therapies for PH-HFpEF, although a number of candidate drugs are being
evaluated, including soluble guanylate cyclase stimulators, phosphodiesterase type 5 inhibitors,
sodium nitrite and endothelin receptor antagonists. In this review we attempt to provide an
updated overview of recent findings pertaining to the pulmonary vascular complications in
HFpEF in terms of clinical definitions, epidemiology and pathophysiology. Mechanisms leading
to pulmonary vascular remodelling in HFpEF, a summary of pre-clinical models of HFpEF
and PH-HFpEF, and new candidate therapeutic strategies for the treatment of PH-HFpEF
are summarized.
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Abstract figure legend Prevalence and pathophysiology of pulmonary hypertension (PH) in patients with heart failure
with preserved ejection fraction (HFpEF). LA, left atrium; LV, left ventricle; LVEDP, left ventricular end-diastolic
pressure; PA, pulmonary artery/arterial; PV, pulmonary vein; PVR, pulmonary vascular resistance; RV, right ventricle.
Pulmonary hypertension (PH) due to left heart disease
(LHD) is the most frequent form of PH and is a growing
public health problem with associated high morbidity
and mortality (Vachiery et al. 2013). PH-LHD was
originally classified under category 2 (pulmonary venous
hypertension) with predominant cause of left-sided
valvular or myocardial diseases by the World Health
Organization (WHO) in 1998. During the Fifth World
Symposium on Pulmonary Hypertension held in Nice,
France in 2013, the classification was updated and the
subcategories of Group 2 PH/PH-LHD were classified
into four distinct aetiologies: left ventricular (LV)
systolic dysfunction, LV diastolic dysfunction, valvular
disease, and congenital/acquired left heart inflow/outflow
tract obstruction and congenital cardiomyopathies
(Simonneau et al. 2013). Most recently, the 2015
European Society of Cardiology (ESC) and the European
Respiratory society (ERS) guidelines further expanded
the definitions to include congenital/acquired pulmonary
vein stenosis in Group 2 PH (Galie et al. 2016a). Among
all of these LHD endophenotypes, PH attributable to LV
diastolic dysfunction, also referred to as PH associated
with heart failure with preserved ejection fraction
(PH-HFpEF), is clearly the most common (Willens
& Kessler, 1993; Lam et al. 2009). Although the true
prevalence of PH-HFpEF remains unknown due to a
general lack of standardization in study design (mostly
retrospective and single centre), with accompanying
variation in the definitions and diagnostic methods used
(most data are based on echocardiography estimation
rather than invasive haemodynamic measurement
with right heart catheterization), the range in the
reported prevalence of PH is between 23% and 83%
of patients with HFpEF (see recent reviews for detailed
information: Vachiery et al. 2013; Guha et al. 2016; Levine
et al. 2018).
Qualitative studies have documented that patients with
PH-HFpEF develop more severe symptoms than those
with HFpEF and suffer significant exercise intolerance,
frequent hospitalizations, right ventricular (RV) failure
and reduced survival (Guazzi, 2014; Mohammed et al.
2014; Dalos et al. 2016; Gorter et al. 2016, 2018b; Santas
et al. 2017; Vanderpool et al. 2018). Despite increasing
interest and a growing number of related publications, no
approved specific medication or consensus therapeutic
strategy for PH-HFpEF is available at present, mainly
due to significant gaps in understanding of the
pathophysiological processes and parameters that can
help to accurately definePH-HFpEF, aswell as the complex
associated comorbidities seen with HFpEF in general
(metabolic syndrome, renal dysfunction, advancing
age, etc.). In this review, we aim to provide an updated
overview of the pulmonary vascular complications in
HFpEF in terms of clinical definitions, epidemiology
and pathophysiology. Mechanisms leading to pulmonary
vascular remodelling in HFpEF, as well as pre-clinical
models which aid evaluation of the putative therapeutic
strategies for the treatment of PH-HFpEF, will also be
discussed.
Definitions, classification of subtypes and diagnostic
factors of PH-HFpEF
One-half of approximately 6.5 million heart failure
patients >20 years of age in the USA are estimated to
C© 2018 The Authors. The Journal of Physiology C© 2018 The Physiological Society
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suffer fromHFpEF (Benjamin et al. 2017). Roughly half of
these patients (awide range from23 to 83%, depending on
the definitions employed) have associated highpulmonary
artery pressures (i.e. PH), imposing an economic burden
of about $7.7 billion per annum (Farr et al. 2016; Savarese
& Lund, 2017).
Evaluation of a patient with suspected PH in HFpEF
requires comprehensive clinical, echocardiographic and
haemodynamic assessments. Exertional dyspnoea and
exercise intolerance are the most common symptoms
in HFpEF patients and, together with orthopnoea and
paroxysmal nocturnal dyspnoea, are often the first clues
to the presence of PH. Individuals with PH-HFpEF
are often elderly, female and more likely to present
with multiple comorbidities, including obesity, diabetes
mellitus, hypertension, renal dysfunction, coronary artery
disease and atrial fibrillation. Findings from physical
examination may reveal signs of fluid retention (e.g.
peripheral oedema, ascites and crackles) and cardiac
examination will reveal the presence of an S3 heart sound.
Additionally, chest X-ray may show pulmonary vascular
congestion, pleural effusion and pulmonary oedema.
Screening echocardiography often reveals evidence of
left atrial enlargement, LV hypertrophy, right atrial
enlargement, LV diastolic dysfunction (e.g. abnormal LV
relaxation, filling, dispensability or diastolic stiffness), and
preserved LV systolic function (e.g. LV ejection fraction
50% and indexed LV end-diastolic volume<97mL/m2)
(Rich & Rabinovitch, 2008; Guazzi & Borlaug, 2012;
Perez et al. 2012). Although mean pulmonary artery
pressure (mPAP) can be estimated by echocardiography
based on tricuspid regurgitant jet velocity, the accuracy
of this is low. Thus, despite echocardiography being a
good screening tool, it should never be used to establish
a diagnosis of PH-HFpEF without proceeding with a
right heart catheterization (Lai et al. 2014). Diagnosis
of PH-HFpEF is typically confirmed when the mPAP
exceeds 25 mmHg and when pulmonary arterial wedge
pressure (PAWP; also called pulmonary capillary wedge
pressure (PCWP) or pulmonary artery occlusion pressure
(PAOP)) is greater than 15 mmHg at rest (Fig. 1). It
is important to note that PAWP should be measured at
end-expiration to minimize respiratory pressure swings.
If there is further concern for coronary disease or
discrepancy from previous right heart catheterization,
left ventricular end-diastolic pressure (LVEDP) can be
measured directly by left heart catheterization (Lai et al.
2014). Elevated plasma levels of brain natriuretic peptide
(BNP) (BNP35 pg/mL and/or N-terminal prohormone
of BNP (NT-proBNP) 125 pg/mL) are also frequently
detected in patientswith PH-HFpEF. Increased LAvolume
and higher pulmonary artery-to-aorta ratio measured by
Blood test
• BMP ≥ 35pg/ml and/or
   NT-proBNP ≥ 125pg/ml 
Chest X-ray
• Pleural effusions
• Pulmonary oedema
• Pulmonary congestion
Echocardiography
• LA/RA enlargement
• LV/RV hypertrophy
• LV diastolic dysfunction
• Preserved LV systolic function
   (eg. LVEF ≥ 50%, LVEDV < 97ml/m2) 
Symptoms and Clinical 
presentations
• Exertional dysnoea and exercise intolerance
• Elderly female (>60 years)
• Present with multiple comorbiditied 
   (eg. obesity, diabetes mellitus, 
   hypertension, renal dysfunction, 
   coronary artery disease, and 
   atrial fibrilation)
Right heart 
catherterization
At rest ≥ 25mmHg > 15mmHg
During exercise* > 30mmHg ≥ 25mmHg
Pre-capillary component
DPG < 7mmHg ≥ 7mmHg
IcPH CpcPHmPAP PAWP
PVR ≤ 3 Wood units > 3 Wood units
Absence Presence
Figure 1. Classification of subtypes and diagnostic factors of PH-HFpEF
CpcPH, combined post-capillary and pre-capillary pulmonary hypertension; DPG, diastolic pressure gradient
(defined as diastolic pulmonary artery pressure – PAWP); IpcPH, isolated post-capillary pulmonary hypertension;
LA, left atrium; LV, left ventricle; LVEF, left ventricular ejection fraction; mPAP, mean pulmonary artery pressure;
PAWP, pulmonary arterial wedge pressure; PVR, pulmonary vascular resistance; RA, right atrium; RV, right ventricle.
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cardiac magnetic resonance, as well as higher size ratio
of left atrium to right atrium measured by non-gated CT
angiography (CTA), may be additional diagnostic features
for identifying patients with PH-HFpEF, although none
of these have been sufficiently validated (Crawley et al.
2013; Karakus et al. 2015; Huis In ’t Veld et al. 2016).
As atrial fibrillation was observed in more than 65% of
HFpEF patients and was correlated with right ventricular
dysfunction in patients with HFpEF, (Zakeri et al. 2013;
Melenovsky et al. 2014; Lam et al. 2017; Sartipy et al. 2017),
it is not surprising that the presence of atrial fibrillation
was reported in 28–48% of patients with PH-HFpEF
(Salamon et al. 2014; Berthelot et al. 2017). Nonetheless,
future studies are needed to determine whether the pre-
sence of atrial fibrillation can be employed as a diagnostic
factor for PH-HFpEF.
While most PH diagnoses rely on resting haemodyna-
mics, HFpEF patients experience worsening symptoms
indicative of PH more often during exercise due to a
number of impairments in cardiovascular reserve function
and skeletal muscle vasodilatory reserve with exercise.
The use of exercise stress testing has been increasingly
recognized as a valuable tool for the reproduction of
symptoms and early diagnosis of PH-HFpEF, especially
in patients with unexplained exertional symptoms and
normal resting haemodynamics or in patients with
intermediate probability of PH-HFpEF (Borlaug et al.
2010; Borlaug et al. 2011; Obokata et al. 2018). The
type of exercise stress testing can vary widely and
may include the six-minute walk test (6MWT), cardio-
pulmonary exercise testing (CPET) and CPET combined
with echocardiography and/or both right and left heart
catheterization. Standard/non-invasive CPET records
parameters such as oxygen uptake (V˙O2), carbon dioxide
production (V˙CO2) and minute ventilation (V˙E) during
exercise, which can aid in diagnosis and risk stratification
of PH-HFpEF as very low upright V˙O2 at peak exercise
(<14mL/kg/min) and increased V˙E/V˙CO2 slope (</36),
have been reported in patients with PH-HFpEF (Borlaug
et al. 2010; Guazzi et al. 2013b; Reddy et al. 2018). Using
invasive CPET, a mPAP cut-off value of >30 mmHg at
a cardiac output (CO) <10 L/min or a total pulmonary
resistance (defined as mPAP/CO) >3 Wood units and a
PAWP cut-off value of 25 mmHg during exercise have
been proposed for the diagnosis of PH in patients with
HFpEF (Fig. 1) (Borlaug et al. 2010; Lewis et al. 2013;
Maor et al. 2015). In a recent study by Obokata et al.,
which employed a simultaneous use of non-invasive and
invasive CPET, it was shown that increased left heart
filling pressure and pulmonary artery pressure during
exercise directly correlated with reduced exercise capacity,
increased ventilatory drive, severity of dyspnoea, altered
breathing patterns, lower RV systolic function, and worse
functional class (Obokata et al. 2018). These data reveal a
new insight into the connection between haemodynamic
derangements, clinical symptoms and gas exchange
alterations in patients with PH-HFpEF. Additionally,
limiteddata suggest that aPAWPcut-off valueof 18mmHg
after fluid challenge with 7 mL/kg saline may be useful
for the diagnosis of patients with post-capillary PH.
Although the use of exercise exposure was suggested
for detection of diastolic dysfunction in the current
guidelines for the diagnosis and treatment of heart failure,
the current guidelines for the diagnosis and treatment
of pulmonary hypertension recommend against the use
of these stress-inducing measures due to insufficient
validation and lack of standardized protocols (Borlaug
et al. 2010; Robbins et al. 2014; Ponikowski et al. 2016;
Galie et al. 2016b; D’Alto et al. 2017; Obokata et al. 2018).
Still, these definitions do not account for the pre-
sence or absence of progressive pulmonary vascular
remodelling (also known as the pre-capillary component)
associated with the development of PH in patients with
HFpEF. Depending on the extent of the pre-capillary
component, the backward transmission of the elevated
LV filling pressure can lead to an increase in pulmonary
artery pressure passively (1:1 ratio) or disproportionately
(>1:1 ratio). Patients with no significant pulmonary
vasoconstriction or pre-capillary component often
exhibit passive/proportional PH (now termed iso-
lated post-capillary PH, IpcPH) and are responsive to
medications which lower their PAWP, such as diuretics,
nitroprusside and other systemic blood pressure control
drug. If, on the other hand, chronically elevated LV
filling pressure triggers pulmonary vasoconstriction and
pathological pre-capillary remodelling to a point of
having increased pulmonary vascular resistance (PVR,
defined as transpulmonary gradient (TPG)/CO) and
high TPG (where TPG is defined as mPAP − PAWP),
patients exhibit out of proportion PH (now termed
combined pre-capillary and post-capillary PH, CpcPH).
While increased PVR (>3 Wood units) and high TPG
(>12mmHg) are commonly used to differentiate patients
with CpcPH from IpcPH (PVR <3 Wood units and
TPG 12 mmHg), these parameters may not accurately
reflect the presence of the pre-capillary component for
their interdependence on CO and PAWP (Galie et al.
2009; Task Force for et al. 2009). As diastolic pressure
gradient (DPG, defined as diastolic PAP − PAWP)
is independent of pulmonary blood flow and is not
influenced by PAWP, a new haemodynamic definition
for distinguishing CpcPH from IpcPH was proposed
based on elevated DPG (7 mmHg) during the Fifth
World Symposium on PH (Stevens, 1975; Buchbinder
& Ganz, 1976; Chemla et al. 2002; Gerges et al.
2013; Vachiery et al. 2013). Beyond diagnosis, recent
reports also showed the prognostic value of DPG, as
elevated DPG was associated with increased mortality
and poor long-term outcomes (Gerges et al. 2013; Ibe
et al. 2016). In accord with this, a large retrospective
C© 2018 The Authors. The Journal of Physiology C© 2018 The Physiological Society
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cohort study (Pittsburgh cohort, single centre with
10,023 subjects undergoing right heart catheterization
during 2005–2012) revealed that multiple haemodynamic
definitions of the pre-capillary component (elevatedDPG,
PVR and TPG) all independently predicted mortality and
cardiac hospitalizations in patients with CpcPH-HFpEF
(Vanderpool et al. 2018). This study found that TPG
>12 mmHg (an easily obtained measure) captures more
patients as having CpcPH and independently predicts
hospitalization and increased mortality in patients with
HFpEF. Furthermore, this study suggested that DPG
measurement can lead tounderestimationofCpcPHbased
on artefactual negative DPG values.
There is an increasing controversy regarding the use
of DPG, as several retrospective studies have shown
that DPG does not have predictive ability for survival
and outcomes (Tedford et al. 2014; Brittain et al. 2015;
Tampakakis et al. 2015; Adir et al. 2017). As mentioned
above, another apparent major problem with using DPG
comes from the reliability of its measurement, since even
small errors in obtainingdiastolic PAP (e.g. negative values
caused by catheter ‘whip’, high frequency noise, excessive
respiratory variation, and/or inadequate calibration) and
PAWP (e.g. inaccurate wedging or large V-waves) may
significantly impact DPG, given its relatively low absolute
value (Tampakakis et al. 2015; Nagy et al. 2017). While
further research is needed to determine whether or not
haemodynamicdefinitionbyDPGis clinicallymeaningful,
the current guidelines included both PVR and DPG,
and redefined IpcPH as DPG <7 mmHg and/or PVR
3 Wood units and CpcPH as DPG 7 mmHg and/or
PVR>3 Wood units (Fig. 1) (Galie et al. 2016b).
Chronic elevation in LV filling pressure and the
progressive pulmonary vascular remodelling leads to
reduced pulmonary artery compliance (PAC, defined as
stroke volume/pulmonary artery pulse pressure), resulting
in RV contractile impairment, increased pulsatile RV
afterload, and eventually right heart failure. Within this
context, PAC has been proposed as a new haemodynamic
marker for diagnosis and prognosis of CpcPH-HFpEF
(Al-Naamani et al. 2015; Dragu et al. 2015; Sugimoto
et al. 2016). Of note, PAC was found as the strongest
predictor of mortality, compared to DPG, PVR and
TPG, with low PAC (<1.1 mL/mmHg) associated with
nearly a fivefold increased risk of death in patients
with PH-HFpEF in a recent study (Al-Naamani et al.
2015). Additionally, index of RV contractile function
and its coupling with pulmonary circulation (RV-PC
coupling), such as measurements of the ratio between
end-systolic elastance (Ees) and arterial elastance (Ea),
as well as the ratio between tricuspid annular plane
systolic excursion (TAPSE) and pulmonary artery systolic
pressure (PASP), were found useful for stratifying clinical
phenotypes and predicting outcomes of patients with
CpcPH-HFpEF. For instance, Gauzzi et al. showed that
depressed TAPSE/PASP ratio predicts CpcPH-HFpEF and
a TAPSE/PASP cut-off ratio of <0.36 is associated with
worse prognosis. Gerges et al. also reported that poor
RV-PC coupling is associated with reduced survival
(Guazzi et al. 2013a, 2017; Gerges et al. 2015; Gorter
et al. 2018a). Most recently, Gorter et al. showed that
CpcPH-HFpEF patients display greater reduction in PA
compliance associated with higher PVR and Ea during
exercise due to impaired RV contractile reserve, suggesting
that measurement of these exercise haemodynamic
parameters is important for identifying CpcPH-HFpEF
patients (Gorter et al. 2018a). This study also provides
new evidence that RV function and functional preserve
may be potential therapeutic targets for management of
CpcPH-HFpEF in the future (Gorter et al. 2018a). The use
of PAC, Ees/Ea and TAPSE/PASP, either at rest or during
exercise, is undergoing validation for clinical utility at
this time.
How common is CpcPH-HFpEF?
Data from several recent catheter-based studies are
available, although varying definitions are being used.
In a large retrospective University of Pittsburgh Medical
Center (UPMC) cohort, the prevalence of a high DPG,
PVR and TPG was evaluated in patients with HFpEF
who had a mean PAP 25 mmHg. In this study the
prevalence of DPG 7 mmHg, PVR 3 Wood units
and TPG >12 mmHg in 2587 patients with PH-HFpEF
was 13.7%, 34.2% and 48.9%, respectively (Vanderpool
et al. 2018). In Austria, retrospective and prospective
studies found CpcPH (DPG 7 mmHg) in 22.6%
and 18.8% of 217 and 138 patients with PH-HFpEF,
respectively (Gerges et al. 2015). A recent study with
the combined Northwestern/San Paolo cohort, CpcPH
(DPG 7 mmHg) was met by 10% of 219 patients with
HFpEF (Guazzi et al. 2017). For a smaller sample size,
a recent multicentre retrospective study across Italy and
Israel found CpcPH (DPG 7 mmHg) in 38% of 86
patients with PH-HFpEF (Adir et al. 2017). In addition, a
prospective cohort at TuftsMedicalCenter found that 36%
of 73 patients with PH-HFpEF met the CpcPH definition
of a DPG7 mmHg (Al-Naamani et al. 2015).
Regardless of whether LVEF is preserved or reduced,
the prevalence of CpcPH in patients with left heart
disease in the UPMC cohort was 11.7%, 36.2% and
45.9%, based on DPG (7 mmHg), PVR (3 Wood
units) and TPG (>12 mmHg), respectively (Vanderpool
et al. 2018). CpcPH (DPG 7 mmHg) was also noted
in 13% of patients with left heart disease in a Johns
Hopkins cohort and 13% of patients with PH in a
Vanderbilt cohort (Tampakakis et al. 2015; Assad et al.
2016; Vanderpool et al. 2018). In cohorts from Austria
and theNetherlands, CpcPH (DPG7mmHg)was noted
C© 2018 The Authors. The Journal of Physiology C© 2018 The Physiological Society
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in 12% of patients with heart failure and in 24.7% of
patients with PH, respectively (Gerges et al. 2015; Gorter
et al. 2018b). In Japan, 3% of heart failure patients met
the CpcPH definition of a DPG 7 mmHg (Ibe et al.
2016). Accordingly, if heart failure affects approximately
6.5 million patients in the USA, then roughly 0.4 million
(ranging between 0.2 and 0.6million) of those patients are
estimated to suffer from CpcPH-HFpEF.
What causes pulmonary vascular complications
in HFpEF?
The left ventricle is designed to be filled with and to eject
blood against the high-resistance systemic circulation,
producing adequate cardiac output of 4–6 L of blood per
minute to provide oxygen to the entire body. Each single
beat of the heart consists of two major components,
diastole, theperiodofLVrelaxation andfilling, and systole,
the period of LV ejection. In a healthy heart, 75–90% of
LV filling occurs during early diastole, and the remainder
of LV filling occurs during late diastole when there is
atrial contraction. The healthy left ventricle can effectively
pull in blood to an adequate preload volume (EDV) at a
normal filling pressure, but in patients withHFpEF, due to
abnormal active relaxation and increased passive stiffness
of the left ventricle, normal cardiac filling and output can
only be achieved by a compensatory elevation in filling
pressure within the left ventricle and a high LA pressure to
push blood into the chamber. In this setting, increased LA
pressure can then back up into the pulmonary circulation,
leading to increased pulmonary venous pressure,
which is in turn transferred to pulmonary capillaries,
causing damage to the alveolar–capillary barrier (also
known as alveolar–capillary stress failure) (West &
Mathieu-Costello, 1995). The alveolar–capillary barrier
of the human lung is extremely thin to allow rapid gas
exchange by passive diffusion. It consists of three layers,
the capillary endothelium, the extracellular matrix (inter-
stitial space) and the alveolar epithelium, with sufficient
strength to maintain its integrity and to limit fluid leak
into the interstitial space and alveolus. Normally, the end-
othelial permeability within the alveolar–capillary barrier
is very low (approximately 4 times less than pulmonary
veins or arteries) with low intracellular Ca2+ levels to
keep the interendothelial junctions closed, and fluid is
continuously cleared from the alveolar surface by Na+
transport through the epithelial sodium channel (ENaC)
and the Na+/K+-ATPase (see reviews in depth by Sukriti
et al. 2014; Huppert & Matthay, 2017). Pressure-induced
elevation of intracellular calcium-mediated endothelial
retraction, activation of the calcium-permeable transient
receptor potential vanilloid 4 (TRPV4) channels, and
impaired resorption of alveolar fluid by ENaC are
apparently involved in disruption of the integrity of
the alveolar–capillary unit, characterized by increased
capillary permeability, fluidfiltration into interstitial space
and reduced fluid removal from the alveolar surface. This
leads to pulmonary oedema, which impairs gas exchange
and leads to hypoxaemia and dyspnoea. When elevation
in filling pressures is sustained, the alveolar–capillary
membrane can undergo a compensatory remodelling
process characterized by increased extracellular matrix
thickening and proliferation, which, along with increased
fluid storage/clearance, protect against pulmonary
oedema in patients with chronic heart failure (Dixon
et al. 2013). However, over time, excessive extracellular
matrix remodelling, inflammation, endothelial dysfunc-
tion, myofibroblasts proliferation and alveolar fluid
reabsorption contribute to a persistent decrease in
capillary–alveolar membrane conductance and gas
exchange, ultimately leading to further dyspnoea with
even mild exertion (see reviews in depth by Dayeh et al.
2016; Guazzi & Naeije, 2017). In fact, a low diffusion
capacity for carbon monoxide (DLCO) of <45% has
been found even at rest in nearly half of the patients with
PH-HFpEF (Hoeper et al. 2016). As disease progresses
further, structural and functional changes regulated by
chronic elevation in capillary pressure also trigger vaso-
constriction and promote remodelling in the pulmonary
arteries and veins, with various combinations of
intimal proliferation, medial hypertrophy and adventitial
thickening (Delgado et al. 2005; Rich&Rabinovitch, 2008;
Chen et al. 2012; Hunt et al. 2013; Lai et al. 2016; Guazzi &
Naeije, 2017; Fayyaz et al. 2018). Particularly noteworthy,
using urokinase plasminogen activator receptor (uPAR)
as an anatomical venousmarker, a recent study found that
intima, media and adventitia in veins and arteries were
significantly remodelled to similar degrees in patients
with PH-LHD and in rats with aortic banding (Hunt et al.
2013). Additionally, medial hypertrophy of muscular
pulmonary arteries appears to be the most common
pathological finding in patients with at-risk PH-LHD.
The greater medial hypertrophy is correlated with higher
pulmonary pressure (Delgado et al. 2005). It is also
noted that pulmonary arterial intimal remodelling is the
least common pathological feature and has the weakest
correlation with PH severity (Lai et al. 2016; Fayyaz
et al. 2018). In a recent study, venous and small vessel
intimal thickening were found to be more severe than
arterial intimal thickening in patients with PH-HFpEF
(Fayyaz et al. 2018). Collectively, the above attributes
describe the patients with CpcPH-HFpEF – patients
whose PH involves remodelling of alveolar–capillary and
pre-capillary small pulmonary arteries in addition to the
passive increase in pulmonary artery pressure. This is in
contrast to the patients with IpcPH-HFpEF, whose PH
simply rises passively in response to the increase in filling
pressure without significant small pulmonary artery
remodelling (Fig. 2).
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Animal models of PH-HFpEF
At present, themanagement of PH-HFpEF ismostly based
on the treatment and relief of theunderlyingHFpEF.While
current guidelines recommend management of optimal
volume and cardiac filling pressure with diuretics and
systemic blood pressure control, no specific therapies are
available for reducing mortality and hospitalization in
patients with PH-HFpEF. Thus, there is an important
unmet need for developing and using animal models to
explore potential mechanisms and new treatment options
for this disease. Current animal models of PH-HFpEF
are adopted from HFpEF models or are developed based
on pathophysiological features, comorbidities and other
confounding factors, including cardiac pressure over-
load models, obesity and diabetes models, metabolic
syndrome models and models that combine all attributes.
Aortic banding, either transverse aortic constriction or
supracoronary aortic banding, is the most common and
successful surgical model for pressure overload-induced
cardiac hypertrophy and HFpEF (Rockman et al. 1991;
Litwin et al. 1995). Aortic-banded mice and rats were
found to develop PH, which was evident from increased
lungweight, pulmonary fibrosis and remodelling, elevated
pulmonary artery pressure and RV hypertrophy (Dai
et al. 2004; Chen et al. 2012; Hunt et al. 2013; Lu et al.
2016). In addition, elevated NT-proBNP plasma levels,
alveolar–capillary wall thickening and perivascular fluid
cuff formation along extra-alveolar vessels were observed
in a recently established aortic-banded cat model of
PH-HFpEF (Wallner et al. 2017). However, aortic banding
models cause acute and severepressureoverload compared
to the chronic process observed in the human disease.
The Dahl salt-sensitive rat, which is hypersensitivity to
sodium intake, is another commonly used model for
HFpEF-based studies. When fed with a high-salt diet
(8% NaCl in most studies) from the age of 7–9 weeks,
Dahl salt-sensitive rats exhibit progressive LV concentric
hypertrophy, diastolic dysfunction, preserved LVEF and
renal failure at the age of 12 weeks (Doi et al. 2000;
Klotz et al. 2006; Lee et al. 2017). Pulmonary oedema
and pulmonary vein fibrosis have also been observed
in this model, but no catheter-based haemodynamics
have been reported (Doi et al. 2000; Nishi et al. 2006;
Iwasaki et al. 2016).
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Figure 2. Pulmonary vascular complications in HFpEF
ENaC, epithelial sodium channel; LA, left atrium; LV, left ventricle; PA, pulmonary artery; PV, pulmonary vein; PVR,
pulmonary vascular resistance; RV, right ventricle.
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While some patients with HFpEF develop CpcPH-
HFpE or IpcPH-HFpEF, it is noted that some patients
never develop PH-HFpEF, suggesting that pathological
changes of pulmonary capillaries and small arteries
in response to increased filling pressure are not the
only factors involved in the development of PH-HFpEF
(Thenappan et al. 2011). Recent studies have found
that features of metabolic syndrome, including obesity,
diabetes, hyperglycaemia, insulin resistance, hypertension
and coronary artery disease (CAD), may affect the
development of PH in the setting of HFpEF (Oktay et al.
2013; Farr et al. 2016). In fact, the prevalence of metabolic
syndrome is observed in more than 94% of patients
with PH-HFpEF (Robbins et al. 2009). The mouse with
leptin deficiency (ob/ob) is the most used obesity and
diabetic animal model. In addition to evident diastolic
dysfunction with impaired LV relaxation, ob/obmice have
been shown to exhibit macrophage infiltration, myo-
fibroblast proliferation, pulmonary arterial remodelling
and RV hypertrophy at the age of 12 weeks (Christoffersen
et al. 2003; Van den Bergh et al. 2008; Aytekin et al. 2014).
The high fat diet (HFD)-fed mouse is another commonly
usedmodel for obesity, impaired glucose tolerance, insulin
resistance, type 2 diabetes and LV diastolic dysfunction.
Komuro & Rosenzweig (1967) reported that combined
HFD (2 g/kg of lanolin, composed of cholesterol and
oxycholesterol) and pneumonectomy induced pulmonary
hypertension and pulmonary atherosclerosis in rabbits.
HFD treatment (60% lipids/kcal, ranging from 8–20
weeks) has also been shown to induce LV hypertrophy,
increasedLVEDPwithpreservedLVEF, pulmonary arterial
remodelling, elevated pulmonary artery pressure and RV
hypertrophy in the most widely used C57BL/6J mice and
in apolipoprotein (apoE)-deficient mice (Hansmann et al.
2007; Kelley et al. 2014, 2017; Meng et al. 2017). Recently,
Kelly et al. exposed 36 inbred and wild-derived mouse
strains to 20 weeks of HFD and identified AKR/J as the
strainmost susceptible toHFD-inducedPH-HFpEF (Kelly
et al. 2017). Of note, the observed increase in severity of
PH in HFD-exposed AKR/J mice (RV systolic pressure
37 mmHg) was close to that observed in patients with
PH-HFpEF (RV systolic pressure range 46–51 mmHg).
Interestingly, despite HFD-treated C57BL/6J and AKR/J
mice developing a comparable degree of obesity, glucose
intolerance and hyperglycaemia, changes in RVSP were
moderate in C57BL/6J mice (Kelly et al. 2017; Meng et al.
2017). Kelly et al. also found that the NOD/ShiLtJ mouse,
which develops autoimmune type 1 diabetes, was themost
resistant strain to HFD-induced PH-HFpEF. In contrast,
theNON/shiLtJmouse,which is sensitive toHFD-induced
type 2 diabetes, was highly susceptible to the development
of PH-HFpEF, suggesting that type 2 diabetes may be
an important pathophysiological abnormality potentially
leading to the development of PH-HFpEF (Kelly et al.
2017; Meng et al. 2017).
Another recently discovered HFpEF model is the
obese ZSF1 rat, which is generated by crossing lean
female Zuker diabetic fatty rats (ZDF, +/fa) with lean
male spontaneous hypertensive heart failure rats (SHHF,
+/facp) (Tofovic et al. 2000). At the age of 8 weeks,
obese ZSF1 rats are diabetic with hyperglycaemia,
dyslipidaemia and hypertension (Bilan et al. 2011). As
disease progresses, obese ZSF1 rats show elevated LVEDP,
preserved LVEF, LV hypertrophy, LA dilatation, increased
cardiomyocyte stiffness, pulmonary congestion, effort
impairment and signs of renal failure at age 20 weeks
(Hamdani et al. 2013; Leite et al. 2015; Franssen et al.
2016; van Dijk et al. 2016). With the combined treatment
of SU5416 (commonly known as Sugen), a vascular
endothelial growth factor (VEGF) receptor blocker
known to induce lung endothelial injury and apoptosis
(Taraseviciene-Stewart et al. 2001), in 8-week-old obese
ZSF1 rats for 14 weeks, the SU5416-exposed obese ZSF1
rats displayed PH-HFpEF characterized by elevated
RV systolic pressure (38 mmHg) accompanied with
increased PVR, pulmonary arterial remodelling and RV
hypertrophy (Lai et al. 2016). Interestingly, a correlation
between impaired glucose uptake by skeletal muscle
and elevated pulmonary pressures was observed using
this model (Lai et al. 2016), suggesting a broader set
of mechanisms contributed by multiple organs may be
involved in the regulation of PH-HFpEF. Additionally,
several large animal models, such as aged dogs with
renal wrapping-induced diastolic dysfunction, Ossabaw
swine with metabolic syndrome and high fat/cholesterol
diet-exposed diabetic pocrine, have demonstrated
the role of ageing and metabolic syndrome in the
development of HFpEF; however, their cardiopulmonary
function and structure require future studies (Munagala
et al. 2005; Trask et al. 2012; van den Heuvel et al.
2012).
Summary and future directions
While we still have no approved specific therapy or even
a consensus treatment strategy at present for patients
with PH in the setting of HFpEF, recent studies have
advanced our knowledge and understanding in terms
of more precise haemodynamic definitions, classification
of subtypes, underlying pathophysiology, standardization
of diagnosis and prognosis methodologies, as well as
the development of new and relevant animal models.
Although the search for effective therapies for PH-HFpEF
remains challenging due to phenotypic heterogeneity of
the disease, substantial efforts made by researchers over
the years have helped to shape a consensus that targeted
therapies to specific subtypes of PH-HFpEF may be
essential for providing a significant positive impact on
patient outcomes.
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We would propose five major areas that could advance
the field:
(1) Precision medicine targeting of the more severe
CpcPH populations of HFpEF and HFrEF. Trials of
PAH-specific drugs have consistently shown clearer
therapeutic signals in the groupswith higher PVR and
lower LVEDP values. Efforts to move forward with
drugs targeting the pulmonary vasculature should
focus on tight management of left ventricular filling
pressures with protocolized diuretic and systemic
blood pressure control regimens while enriching the
cohort for intervention with patients with high PVR,
TPG or DPG values. Efforts to consider this group
with CpcPH an ‘orphan disease’ population with
the FDA seems appropriate and will advance the
field, based on the cost and challenge of strict end-
ophenotyping populations.
(2) Considering the use of provoked response as an end-
point (e.g. exercise haemodynamics and capacity).
While the use of haemodynamic exercise testing and/
or fluid challenge are at present not included in
the current recommended guidelines, more effort is
required to assess whether the use of these methods
can be valuable in future diagnostic and prognostic
evaluations.
(3) Developing drugs that target the pulmonary
vasculature and metabolic features of disease.
New mechanism-based therapeutics should attempt
to target the diverse phenotype of disease by
improving metabolism and pulmonary vascular
remodelling. Suggested models include AMPK and
sirtuin activators based on metformin, perhaps in
combination with pulmonary vasodilatory agents,
similar to experiences with nitrite and metformin
(Lai et al. 2016). Combination therapy targeting the
pulmonary vasculature, metabolic syndrome and left
ventricular relaxation may be required.
(4) Limiting the confounding effect of deconditioning.
In our experience, our HFpEF patients are extremely
sedentary and deconditioned. Simple participation
in our trials increases their activity and confidence
in ability to exercise, with observed effects that are
much greater than the ‘learning effect’ observed with
repeat six-minute walk testing. This creates back-
ground noise for any outcome measure based on
exercise. We would propose lead-in cardiopulmonary
rehabilitation prior to enrolment, similar to strategies
that were shown effective with lung volume reduction
surgery (Fishman et al. 2001, 2003).
(5) Continuing to advance development of robust
and predictive pre-clinical models of HFpEF and
PH-HFpEF. Ultimately, the field may be advanced
by the discovery of molecular therapies that directly
improve the diastolic function of the left ventricle at
rest and during exercise or fluid challenge stress. It
will be necessary to test these agents in appropriate
models and then advance to the clinic in well-defined
patient populations.
In conclusion, establishing a definitive consensus for
haemodynamic phenotyping is still a critical first step
in providing important new insights into this emerging
disease and in driving the research field of PH-HFpEF
forward. As individuals with phenotypic variations are
noted to have different response to drug treatments, future
trials with well-defined and carefully selected patient
populations may help to identify the corresponding pre-
vention and treatment strategies. Finally, referral to PH
care centres is recommended for treatment of patients in
aneffort tooptimize clinical decisionmakingandpotential
outcome.
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